Request a copy

Full Text

16

CITATIONS

16 Total citations

1 Recent citation

2.74 Field Citation Ratio

0.27 Relative Citation Ratio

publications

0

supporting

0

mentioning

0

contrasting

0

Smart Citations

0

0

0

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

• Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Central Brain Tumor Registry of the United States Statistical Report; 2010.
• Daly A.F., Rixhon M., Adam C., Dempegioti A., Tichomirowa M.A., Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006, 91:4769-4775.
• Davis J.R., Farrell W.E., Clayton R.N. Pituitary tumours. Reproduction 2001, 121:363-371.
• Herman V., Fagin J., Gonsky R., Kovacs K., Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990, 71:1427-1433.
• Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954, 16:363-371.
• Daly A.F., Jaffrain-Rea M.L., Ciccarelli A., Valdes-Socin H., Rohmer V., Tamburrano G., et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006, 91:3316-3323.
• Scheithauer B.W., Laws E.R., Kovacs K., Horvath E., Randall R.V., Carney J.A. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol 1987, 4:205-211.
• Lemos M.C., Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008, 29:22-32.
• Stratakis C.A., Kirschner L.S., Carney J.A. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001, 86:4041-4046.
• Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., Samson E., Bink K., Hofler H., et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006, 103:15558-15563.
• Valdes Socin H., Poncin J., Stevens V., Stevenaert A., Beckers A Adenomes hypophysaires familiaux isolés non liés avec la mutation somatique NEM-1. Suivi de 27 patients. Ann Endocrinol Paris 2000, 61:301.
• Beckers A. Familial isolated pituitary adenomas. J Intern Med. 2004;255:698, [ou Tichomirowa MA, Daly AF, Beckers A. Familial pituitary adenomas. J Intern Med 2009;266(1):5-18].
• Beckers A., Daly A.F. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 2007, 157:371-382.
• Vierimaa O., Georgitsi M., Lehtonen R., Vahteristo P., Kokko A., Raitila A., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
• Daly A.F., Vanbellinghen J.F., Khoo S.K., Jaffrain-Rea M.L., Naves L.A., Guitelman M.A., et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007, 92:1891-1896.
• Poncin J., Stevenaert A., Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. Eur J Endocrinol 1999, 140:573-576.
• Barlier A., Vanbellinghen J.F., Daly A.F., Silvy M., Jaffrain-Rea M.L., Trouillas J., et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab 2007, 92:1952-1955.
• Landis C.A., Masters S.B., Spada A., Pace A.M., Bourne H.R., Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989, 340:692-696.
• Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86:5658-5671.
• Chandrasekharappa S.C., Guru S.C., Manickam P., Olufemi S.E., Collins F.S., Emmert-Buck M.R., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276:404-407.
• Sayo Y., Murao K., Imachi H., Cao W.M., Sato M., Dobashi H., et al. The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells. Endocrinology 2002, 143:2437-2440.
• La P., Schnepp R.W.C.D.P.A., Hua C.S.X. Tumor suppressor menin regulates expression of insulin-like growth factor binding protein 2. Endocrinology 2004, 145:3443-3450.
• Namihira H., Sato M., Murao K., Cao W.M., Matsubara S., Imachi H., et al. The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. J Mol Endocrinol 2002, 29:297-304.
• Scacheri P.C., Davis S., Odom D.T., Crawford G.E., Perkins S., Halawi M.J., et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet 2006, 2:e51.
• Hughes C.M., Rozenblatt-Rosen O., Milne T.A., Copeland T.D., Levine S.S., Lee J.C., et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell. 2004, 13:587-597.
• Horvath A., Stratakis C.A. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab Disord 2008, 9:1-11.
• Pfarr C.M., Mechta F., Spyrou G., Lallemand D., Carillo S., Yaniv M. Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. Cell 1994, 76:747-760.
• Heppner C., Bilimoria K.Y., Agarwal S.K., Kester M., Whitty L.J., Guru S.C., et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001, 20:4917-4925.
• Kaji H., Canaff L., Lebrun J.J., Goltzman D., Hendy G.N. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci U S A. 2001, 98:3837-3842.
• Farid N.R., Buehler S., Russell N.A., Maroun F.B., Allerdice P., Smyth H.S. Prolactinomas in familial multiple endocrine neoplasia syndrome type I. Relationship to HLA and carcinoid tumors. Am J Med. 1980, 69:874-880.
• Olufemi S.E., Green J.S., Manickam P., Guru S.C., Agarwal S.K., Kester M.B., et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum Mutat 1998, 11:264-269.
• Burgess J.R., Nord B., David R., Greenaway T.M., Parameswaran V., Larsson C., et al. Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN 1). Clin Endocrinol (Oxf) 2000, 53:205-211.
• Verges B., Boureille F., Goudet P., Murat A., Beckers A., Sassolas G., et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002, 87:457-465.
• Bertolino P., Tong W.M., Galendo D., Wang Z.Q., Zhang C.X. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol 2003, 17:1880-1892.
• Biondi C.A., Gartside M.G., Waring P., Loffler K.A., Stark M.S., Magnuson M.A., et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol 2004, 24:3125-3131.
• Piotrowska K., Pellegata N.S., Rosemann M., Fritz A., Graw J., Atkinson M.J. Mapping of a novel MEN-like syndrome locus to rat chromosome 4. Mamm Genome 2004, 15:135-141.
• Georgitsi M., Raitila A., Karhu A., van der Luijt R.B., Aalfs C.M., Sane T., et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007, 92:3321-3325.
• Agarwal S.K., Mateo C.M., Marx S.J. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 2009, 94:1826-1834.
• Igreja S., Chahal H.S., Akker S.A., Gueorguiev M., Popovic V., Damjanovic S., et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol (Oxf) 2009, 70:259-264.
• Karnik S.K., Hughes C.M., Gu X., Rozenblatt-Rosen O., McLean G.W., Xiong Y., et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005, 102:14659-14664.
• Drosten M., Hilken G., Bockmann M., Rodicker F., Mise N., Cranston A.N., et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 2004, 96:1231-1239.
• Kolluri S.K., Weiss C., Koff A., Gottlicher M. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev 1999, 13:1742-1753.
• Stratakis C.A., Carney J.A., Lin J.P., Papanicolaou D.A., Karl M., Kastner D.L., et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest 1996, 97:699-705.
• Boikos S.A., Stratakis C.A. Carney complex: the first 20 years. Curr Opin Oncol 2007, 19:24-29.
• Kirschner L.S., Carney J.A., Pack S.D., Taymans S.E., Giatzakis C., Cho Y.S., et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000, 26:89-92.
• Bossis I., Stratakis C.A. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 2004, 145:5452-5458.
• Boikos S.A., Stratakis C.A. Pituitary pathology in patients with Carney Complex: growth-hormone producing hyperplasia or tumors and their association with other abnormalities. Pituitary. 2006, 9:203-209.
• Pack S.D., Kirschner L.S., Pak E., Zhuang Z., Carney J.A., Stratakis C.A. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the " complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). J Clin Endocrinol Metab. 2000, 85:3860-3865.
• Yin Z., Williams-Simons L., Parlow A.F., Asa S., Kirschner L.S. Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol Endocrinol 2008, 22:380-387.
• Bailey P., Cushing H. Studies in Acromegaly: VII. The Microscopical Structure of the Adenomas in Acromegalic Dyspituitarism (Fugitive Acromegaly). Am J Pathol 1928, 4:545-564. 13.
• Verloes A., Stevenaert A., Teh B.T., Petrossians P., Beckers A. Familial acromegaly: case report and review of the literature. Pituitary. 1999, 1:273-277.
• Luccio-Camelo D.C., Une K.N., Ferreira R.E., Khoo S.K., Nickolov R., Bronstein M.D., et al. A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur J Endocrinol. 2004, 150:643-648.
• Linquette M., Herlant M., Laine E., Fossati P., Dupont-Lecompte J. Adénome a prolactine chez une jeune fille dont la mère était porteuse d'un adénome hypophysaire avec aménorrhée-galactorrhée. Ann Endocrinol Paris 1967, 28:773-780.
• Berezin M., Karasik A. Familial prolactinoma. Clin Endocrinol (Oxf). 1995, 42:483-486.
• Salti I.S., Mufarrij I.S. Familial Cushing Disease. Am J Med Genet 1981, 8:91-94.
• Yuasa H., Tokito S., Nakagaki H., Kitamura K. Familial pituitary adenoma-report of four cases from two unrelated families. Neurol Med Chir (Tokyo) 1990, 30:1016-1019.
• Valdes-Scoin H JRM, Tamburrano G, Cavagnini F, Cicarelli E, Colao A, Delemer B, Brue T, Rohmer V, Wemeau JL, Levasseur S, The B, Stevenaert A, Beckers A. Familial isolated pituitary tumors: clinical and molecular studies in 80 patients. Endocrine Society's 84th Annual Meeting. 2002:P3-663, 47.
• Carver L.A., Bradfield C.A. Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J Biol Chem 1997, 272:11452-11456.
• Oesch-Bartlomowicz B., Oesch F. Role of cAMP in mediating AHR signaling. Biochem Pharmacol. 2009, 77:627-641.
• Lees M.J., Peet D.J., Whitelaw M.L. Defining the role for XAP2 in stabilization of the dioxin receptor. J Biol Chem 2003, 278:35878-35888.
• Bolger G.B., Peden A.H., Steele M.R., MacKenzie C., McEwan D.G., Wallace D.A., et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem 2003, 278:33351-33363.
• de Oliveira S.K., Hoffmeister M., Gambaryan S., Muller-Esterl W., Guimaraes J.A., Smolenski A.P. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J Biol Chem 2007, 282:13656-13663.
• Leontiou C.A., Gueorguiev M., van der Spuy J., Quinton R., Lolli F., Hassan S., et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008, 93:2390-2401.
• Lin B.C., Sullivan R., Lee Y., Moran S., Glover E., Bradfield C.A. Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J Biol Chem 2007, 282:35924-35932.
• Carver L.A., LaPres J.J., Jain S., Dunham E.E., Bradfield C.A. Characterization of the Ah receptor-associated protein ARA9. J Biol Chem 1998, 273:33580-33587.
• Bell D.R., Poland A. Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of HSP90. J Biol Chem 2000, 275:36407-36414.
• Burlacu M.C., Tichomirowa M., Daly A., Beckers A. Familial pituitary adenomas. Presse Med 2009, 38:112-116.
• Toledo R.A., Lourenco D.M., Liberman B., Cunha-Neto M.B., Cavalcanti M.G., Moyses C.B., et al. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab 2007, 92:1934-1937.
• Iwata T., Yamada S., Mizusawa N., Golam H.M., Sano T., Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin Endocrinol (Oxf) 2007, 66:499-502.
• Georgitsi M., Raitila A., Karhu A., Tuppurainen K., Makinen M.J., Vierimaa O., et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci U S A 2007, 104:4101-4105.
• Georgitsi M., Karhu A., Winqvist R., Visakorpi T., Waltering K., Vahteristo P., et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br J Cancer 2007, 96:352-356.
• Cazabat L., Libe R., Perlemoine K., Rene-Corail F., Burnichon N., Gimenez-Roqueplo A.P., et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 2007, 157:1-8.
• Ozfirat Z, Korbonits M. AIP gene and familial isolated pituitary adenomas. Mol Cell Endocrinol. 2010 May 8. [Epub ahead of print].
• Cazabat L., Guillaud-Bataille M., Bertherat J., Raffin-Sanson M.L. Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. Horm Res 2009, 71:132-141.
• Naves L.A., Daly A.F., Vanbellinghen J.F., Casulari L.A., Spilioti C., Magalhaes A.V., et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur J Endocrinol. 2007, 157:383-391.
• Tichomirowa M.A., Daly A.F., Beckers A. Familial pituitary adenomas. J Intern Med. 2009, 266:5-18.
• Jaffrain-Rea M.L., Angelini M., Gargano D., Tichomirowa M.A., Daly A.F., Vanbellinghen J.F., et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer 2009, 16:1029-1043.